DENTSPLY (XRAY) Q3 Earnings Beat Estimates, Sales Rise Y/Y

DENTSPLY SIRONA Inc. XRAY is one of the leading worldwide manufacturers’ dental consumables, dental laboratory products, dental specialty products and consumable medical device products. Post DENTSPLY-SIRONA merger, the business has been organized into two reporting segments: Dental & Healthcare Consumables and Technologies.

Currently, this York, PA- based company carries a Zacks Rank #3 (Hold) but that could change following its third quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:

Earnings: DENTSPLY reported adjusted earnings of 70 cents per share, which came above the Zacks Consensus Estimate by 4 cents and was higher than earnings of 66 cents in the year-ago quarter.

Revenues: DENTSPLY’s net sales increased to $1,009.2 million from $954.0 million in the year-ago period. This also came above the Zacks Consensus Estimate of $978.0 million. Net sales, excluding precious metals, increased 4.3% on a constant currency basis and internal growth was 2.4% as compared to the third quarter of 2016.

Narrowed Guidance: The company narrowed its adjusted EPS guidance for 2017 to the range of $2.65 to $2.70 per share. Earlier, the company projected adjusted EPS in a range of $2.65 to $2.75.

Check back later for our full write up on this DENTSPLY earnings report later!

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research